RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
Check-point inhibitor
Durvalumab
MAMS
Platform trial
RAMPART
Renal cancer
Tremelimumab
Journal
Contemporary clinical trials
ISSN: 1559-2030
Titre abrégé: Contemp Clin Trials
Pays: United States
ID NLM: 101242342
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
18
03
2021
revised:
07
06
2021
accepted:
09
06
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
27
10
2021
Statut:
ppublish
Résumé
20-60% of patients with initially locally advanced Renal Cell Carcinoma (RCC) develop metastatic disease despite optimal surgical excision. Adjuvant strategies have been tested in RCC including cytokines, radiotherapy, hormones and oral tyrosine-kinase inhibitors (TKIs), with limited success. The predominant global standard-of-care after nephrectomy remains active monitoring. Immune checkpoint inhibitors (ICIs) are effective in the treatment of metastatic RCC; RAMPART will investigate these agents in the adjuvant setting. RAMPART is an international, UK-led trial investigating the addition of ICIs after nephrectomy in patients with resected locally advanced RCC. RAMPART is a multi-arm multi-stage (MAMS) platform trial, upon which additional research questions may be addressed over time. The target population is patients with histologically proven resected locally advanced RCC (clear cell and non-clear cell histological subtypes), with no residual macroscopic disease, who are at high or intermediate risk of relapse (Leibovich score 3-11). Patients with fully resected synchronous ipsilateral adrenal metastases are included. Participants are randomly assigned (3,2:2) to Arm A - active monitoring (no placebo) for one year, Arm B - durvalumab (PD-L1 inhibitor) 4-weekly for one year; or Arm C - combination therapy with durvalumab 4-weekly for one year plus two doses of tremelimumab (CTLA-4 inhibitor) at day 1 of the first two 4-weekly cycles. The co-primary outcomes are disease-free-survival (DFS) and overall survival (OS). Secondary outcomes include safety, metastasis-free survival, RCC specific survival, quality of life, and patient and clinician preferences. Tumour tissue, plasma and urine are collected for molecular analysis (TransRAMPART). ISRCTN #: ISRCTN53348826, NCT #: NCT03288532, EUDRACT #: 2017-002329-39, CTA #: 20363/0380/001-0001, MREC #: 17/LO/1875, ClinicalTrials.gov Identifier: NCT03288532, RAMPART grant number: MC_UU_12023/25, TransRAMPART grant number: A28690 Cancer Research UK, RAMPART Protocol version 5.0.
Sections du résumé
BACKGROUND
20-60% of patients with initially locally advanced Renal Cell Carcinoma (RCC) develop metastatic disease despite optimal surgical excision. Adjuvant strategies have been tested in RCC including cytokines, radiotherapy, hormones and oral tyrosine-kinase inhibitors (TKIs), with limited success. The predominant global standard-of-care after nephrectomy remains active monitoring. Immune checkpoint inhibitors (ICIs) are effective in the treatment of metastatic RCC; RAMPART will investigate these agents in the adjuvant setting.
METHODS/DESIGN
RAMPART is an international, UK-led trial investigating the addition of ICIs after nephrectomy in patients with resected locally advanced RCC. RAMPART is a multi-arm multi-stage (MAMS) platform trial, upon which additional research questions may be addressed over time. The target population is patients with histologically proven resected locally advanced RCC (clear cell and non-clear cell histological subtypes), with no residual macroscopic disease, who are at high or intermediate risk of relapse (Leibovich score 3-11). Patients with fully resected synchronous ipsilateral adrenal metastases are included. Participants are randomly assigned (3,2:2) to Arm A - active monitoring (no placebo) for one year, Arm B - durvalumab (PD-L1 inhibitor) 4-weekly for one year; or Arm C - combination therapy with durvalumab 4-weekly for one year plus two doses of tremelimumab (CTLA-4 inhibitor) at day 1 of the first two 4-weekly cycles. The co-primary outcomes are disease-free-survival (DFS) and overall survival (OS). Secondary outcomes include safety, metastasis-free survival, RCC specific survival, quality of life, and patient and clinician preferences. Tumour tissue, plasma and urine are collected for molecular analysis (TransRAMPART).
TRIAL REGISTRATION
ISRCTN #: ISRCTN53348826, NCT #: NCT03288532, EUDRACT #: 2017-002329-39, CTA #: 20363/0380/001-0001, MREC #: 17/LO/1875, ClinicalTrials.gov Identifier: NCT03288532, RAMPART grant number: MC_UU_12023/25, TransRAMPART grant number: A28690 Cancer Research UK, RAMPART Protocol version 5.0.
Identifiants
pubmed: 34538402
pii: S1551-7144(21)00218-4
doi: 10.1016/j.cct.2021.106482
pmc: PMC8520913
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT03288532']
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106482Subventions
Organisme : Medical Research Council
ID : MC_UU_00004/01
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00004/09
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom
Informations de copyright
Crown Copyright © 2021. Published by Elsevier Inc. All rights reserved.
Références
N Engl J Med. 2021 Apr 8;384(14):1289-1300
pubmed: 33616314
Clin Trials. 2020 Jun;17(3):273-284
pubmed: 32063029
J Urol. 2005 Aug;174(2):466-72; discussion 472; quiz 801
pubmed: 16006866
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
JAMA Oncol. 2017 Sep 1;3(9):1249-1252
pubmed: 28278333
World J Urol. 2016 Aug;34(8):1081-6
pubmed: 26847337
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
J Clin Oncol. 2017 Dec 10;35(35):3916-3923
pubmed: 28902533
Eur Urol Focus. 2019 Sep;5(5):857-866
pubmed: 29525381
Ann Oncol. 2018 Dec 1;29(12):2371-2378
pubmed: 30346481
J Clin Oncol. 2020 Dec 1;38(34):4064-4075
pubmed: 33052759
Contemp Clin Trials. 2021 Sep;108:106482
pubmed: 34538402
N Engl J Med. 2021 Mar 4;384(9):829-841
pubmed: 33657295
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
N Engl J Med. 2016 Dec 8;375(23):2246-2254
pubmed: 27718781
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Eur Urol Focus. 2016 Feb;1(3):251-257
pubmed: 28723393
Contemp Clin Trials. 2021 Sep;108:106481
pubmed: 34538401
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
Eur Urol. 2021 Mar;79(3):334-338
pubmed: 33461782
Cancer. 2003 Apr 1;97(7):1663-71
pubmed: 12655523
Eur Urol. 2018 Jan;73(1):62-68
pubmed: 28967554